-
Founded in:
1991-10-12 -
Country:
China -
Address:
No. 1 Shangguafan, Jinnan Street, Lin'an District, Hangzhou City, Zhejiang Province -
Tax NO.:
91330100609129453D -
Registered Funds:
$54,333,333 -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aripiprazole |
Antipsychotic effects through partial agonism of D2 and 5-HT1A receptors and antagonism of 5-HT2A receptors
More
Antipsychotic effects through partial agonism of D2 and 5-HT1A receptors and antagonism of 5-HT2A receptors |
129722-12-9 | 81 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tolvaptan |
A vasopressin V2 receptor antagonist (non-peptide AVP2 receptor antagonist) that can increase the sodium ion concentration in plasma and help excess water be excreted from the urine. Enhance the kidney's ability to process water. Cyclic adenosine monophosphate (cAMP) accumulates in polycystic kidney cells, which promotes cyst growth by stimulating cyst fluid secretion and lining cell proliferation. Tolvaptan is a type 2 vasopressin receptor antagonist that inhibits cAMP generation and accumulation. In a variety of PKD animal model studies, tolvaptan has shown good efficacy.
More
A vasopressin V2 receptor antagonist (non-peptide AVP2 receptor antagonist) that can increase the sodium ion concentration in plasma and help excess water be excreted from the urine. Enhance the kidney's ability to process water. Cyclic adenosine monophosphate (cAMP) accumulates in polycystic kidney cells, which promotes cyst growth by stimulating cyst fluid secretion and lining cell proliferation. Tolvaptan is a type 2 vasopressin receptor antagonist that inhibits cAMP generation and accumulation. In a variety of PKD animal model studies, tolvaptan has shown good efficacy. |
150683-30-0 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tolvaptan |
A vasopressin V2 receptor antagonist (non-peptide AVP2 receptor antagonist) that can increase the sodium ion concentration in plasma and help excess water be excreted from the urine. Enhance the kidney's ability to process water. Cyclic adenosine monophosphate (cAMP) accumulates in polycystic kidney cells, which promotes cyst growth by stimulating cyst fluid secretion and lining cell proliferation. Tolvaptan is a type 2 vasopressin receptor antagonist that inhibits cAMP generation and accumulation. In a variety of PKD animal model studies, tolvaptan has shown good efficacy.
More
A vasopressin V2 receptor antagonist (non-peptide AVP2 receptor antagonist) that can increase the sodium ion concentration in plasma and help excess water be excreted from the urine. Enhance the kidney's ability to process water. Cyclic adenosine monophosphate (cAMP) accumulates in polycystic kidney cells, which promotes cyst growth by stimulating cyst fluid secretion and lining cell proliferation. Tolvaptan is a type 2 vasopressin receptor antagonist that inhibits cAMP generation and accumulation. In a variety of PKD animal model studies, tolvaptan has shown good efficacy. |
150683-30-0 | 23 |